When to consider alternatives to front-line immune therapies in metastatic melanoma
Melanoma Manag
.
2017 May;4(2):71-74.
doi: 10.2217/mmt-2017-0005.
Epub 2017 May 10.
Authors
Daniel Y Wang
1
,
Douglas B Johnson
1
Affiliation
1
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
PMID:
30190906
PMCID:
PMC6094648
DOI:
10.2217/mmt-2017-0005
No abstract available
Keywords:
immunotherapy; melanoma; targeted therapy.
Publication types
Editorial
Grants and funding
K12 CA090625/CA/NCI NIH HHS/United States